Slide 1: Investor Presentation: Transforming minimally invasive neurosurgery
Ticker: MRIC Investor Presentation August 18, Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements often can be identified by words such as “a
Slide 3: MRI Interventions Investment Opportunity
MRI Interventions Investment Opportunity Commercial Business Focused commercial effort in neurosurgery; FDA/CE cleared products Enabling real-time MRI guided surgery; FDA-cleared, CE- marked and 45+ ClearPoint sites; growing procedure business Drug Delivery Upside Growing Presence in Drug Delivery C
Slide 4: Experienced, Medical Device Leadership Team
Experienced, Medical Device Leadership Team Key Management Executive Frank Grillo Peter Piferi Wendelin Maners Robert Korn Hal Hurwitz Title President, CEO COO VP Marketing VP Sales CFO Prior Experience Board of Directors Kimble Jenkins, Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Frank Grill
Slide 5: ClearPoint Neuro Navigation System
ClearPoint® Neuro Navigation System Utilizes an existing diagnostic or intraoperative MRI to enable real time, intra-operative MRI Imaging during Neurosurgery ClearPoint Software Proprietary software for targeting and trajectory calculation / determination Dicom image based MRI Safe Hardware MRI saf
Slide 6: Key Procedures for Our Technology
Key Procedures for Our Technology …and the challenges we address Therapies Deep Brain Stimulation Medtronic St. Jude* Boston Scientific* Laser Ablation Visualase/Medtronic Monteris Drugs/Biologics Voyager UniQure Merrimack Int’l Stem Cell Medicenna Plus others Patient Populations Parkinson’s Disease
Slide 7: Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed Blind
Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed “Blind” Conventional Stereotactic Procedure No real time images – images from earlier in the day or week ClearPoint Neuro Procedure 80% of interviewed neurosurgeons/neurologists believe real time MRI-guidance will or can become th
Slide 8: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning © 2016 MRI INTERVENTIONS, INC. | 8
Slide 9: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview SmartFrame® Trajectory Guide SmartFrame® Hand Controller Trajectory Alignment & Device Insertion © 2016 MRI INTERVENTIONS, INC. | 9
Slide 10: Clinical Support, Validation
Clinical Support, Validation Notable Neurosurgeon Supporters Dr. Philip Starr ASSFN Past President Dr. Paul Larson UCSF & VA Dr. Robert Gross Emory University Dr. Robert Wharen, Jr. Mayo Clinic - Jacksonville Dr. Krys Bankiewicz Bankiewicz Lab, UCSF Dr. Russ Lonser OSU - NIH Published Peer-Reviewed
Slide 11: Patented Intellectual Property
Patented Intellectual Property Over 100 issued patents around the world 20+ U.S. 30+ OUS 70+ U.S. Patents 45+ OUS Patents Patent Applications Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrame® trajectory guide; other
Slide 12: MRIC's Unique Opportunity in Drug Delivery
MRIC‘s Unique Opportunity in Drug Delivery Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery (pills, shots, IV) of almost all drugs – 98% of small molecules - Direct injection without ClearPoint is blind, so target is frequently missed - Neopharm Trial
Slide 13: ClearPoint Drug Delivery w/ SmartFlow Cannula
ClearPoint Drug Delivery w/ SmartFlow Cannula MR visualization of neuro target MR-guided placement of catheter Therapeutic agent delivered under MR-guidance* Specialized, FDA-cleared drug delivery cannula’s / catheters Drug infusion is visible under real- time MRI Growing Set of Peer-reviewed Public
Slide 14: ClearPoint's Use in Drug Delivery
ClearPoint‘s Use in Drug Delivery Seven Programs Underway Now... Current Drug Delivery Trials Utilizing the ClearPoint System: AAV2-hAADC for Parkinson’s disease Phase 1 Study at UCSF Initial sponsorship by Michael J. Fox Foundation AAV2-GDNF for Parkinson’s disease Phase 1 Study at the NIH MDNA55 f
Slide 15: ClearPoint Revenue Model
ClearPoint Revenue Model BUSINESS MODEL – RAZOR/RAZORBLADE ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered by existing inpatient DRG reim
Slide 16: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 44 sites in the US Europe: Warsaw, Poland © 2016 MRI INTERVENTIONS, INC. | 16
Slide 17: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity Total Prevalence (US) Prevalence – Drug Treatment Resistant (DTR) Incidence – DTR ClearPoint Enabled Therapy Potential ClearPoint Procedures, Annually2 Parkinson’s 1,500,000 125,000 7,500 Electrode Placement (DBS) 12,500 Epilepsy 2,200,000 264,000 18,000 Laser Ablati
Slide 18: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues Consumables $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q3 Q4 2013 Q1 Q2 Q3 Q4 2014 Q1 Q2 Q3 Q4 2015 Q1 Q2 2016 © 2016 MRI INTERVENTIONS, INC. | 18
Slide 19: Total Revenue, 2013 - 2016
Total Revenue, 2013 - 2016 Total Revenue $1,600,000 $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2013 2014 2015 2016 Consumables Capital / Service Other © 2016 MRI INTERVENTIONS, INC. | 19
Slide 20: Cash Flow From Operations
Cash Flow From Operations $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Payment of $739,000 in accrued interest to Brainlab, as part of note restructuring Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2014 2015 2016 © 2016 MRI INTERVENTIONS, INC. | 20
Slide 21: Leading a New, Emerging Industry Trend
Leading a New, Emerging Industry Trend © 2016 MRI INTERVENTIONS, INC. | 21
Slide 22: MRI Interventions, Inc. contact
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 www.mriinterventions.co m Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 22